- $2.37bn
- $1.64bn
- $630.20m
- 43
- 26
- 48
- 33
RCS - Hutchmed China Ltd - HUTCHMED Data to be Presented at EHA2024 Congress
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Phase II/III Trial with Hengrui
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Registrational Phase III Trial
AnnouncementREG - Hutchmed China Ltd - Result of AGM
AnnouncementREG - Hutchmed China Ltd - Directorate Change
AnnouncementREG - Hutchmed China Ltd - Positive CHMP Opinion for Fruquintinib
AnnouncementREG - Hutchmed China Ltd - Vesting of Awards Under the LTIP
AnnouncementREG - Hutchmed China Ltd - 2023 Annual Report and Notice of AGM
AnnouncementRCS - Hutchmed China Ltd - Data to be Presented at AACR Congress 2024
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance
AnnouncementRCS - Hutchmed China Ltd - Savolitinib sNDA Accepted in China
AnnouncementRCS - Hutchmed China Ltd - Initiation of Registration Stage of P2/3 Trial
AnnouncementREG - Hutchmed China Ltd - LTIP and Share Option Scheme
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2023 Full Year Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Presentation of Phase III Data on Fruquintinib
AnnouncementRCS - Hutchmed China Ltd - Inmagene Exercises Option for Two Drug Candidates
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2023 Final Results
Announcement